Our results were in accordance with previous studies in PCNSL, AITL, and PTCL (73, 74), indicating the predictive treatment effects and prognosis of MYC in EBV+ DLBCL patients. The gene discussed is MYC; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.